Amgen Blood Cancer Drug Succeeds in Late-Stage Study
By Reuters Staff
Amgen Inc said a late-stage study found that its blood cancer drug Kyprolis (carfilzomib) helped patients live significantly longer without the disease worsening, compared with standard treatment.
The U.S. Food and Drug Administration, in 2012, granted the drug accelerated approval for use in multiple myeloma, the second most common form of blood cancer.
Accelerated approval is granted to drugs for serious diseases with little or no treatment options, based on data from initial trials. However, manufacturers still need to conduct larger trials to bolster initial findings.
The trial tested Kyprolis in combination with lenalidomide and dexamethasone, against those two treatments alone, in 792 patients with relapsed multiple myeloma who have received prior therapy.
Patients treated with Kyprolis lived for a median of 26.3 months without disease progression, compared with 17.6 months for those not given the drug, Amgen said.
The results will be submitted for presentation at the upcoming 56th Annual Meeting of the American Society of Hematology later this year.
(c) Copyright Thomson Reuters 2014. Click For Restrictions - http://about.reuters.com/fulllegal.asp
‹ Previous articleNext article ›